Safety and Performance of Dafodil Heart Valves in Real-World Aortic and Mitral Valve Replacement

NCT07379112 | Not Yet Recruiting

• 1 other identifier: MLS/EURODAF-1
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study, called the EuroDafodil Registry, is being conducted to understand how safe and effective the Dafodil™ and Dafodil Neo™ Pericardial Bioprosthetic heart valves are when used in routine medical practice. The registry includes adult patients (18 years or older) who require surgical replacement of their aortic or mitral heart valve, either because their natural valve is severely diseased or because a previously implanted valve is no longer working properly. All patients in this registry will receive a Dafodil™ heart valve as part of their standard surgical treatment. No experimental procedures are involved beyond usual clinical care. This is a prospective, multi-centre registry being conducted at approximately 50 hospitals across Europe, with a planned enrollment of at least 500 patients. The study does not compare treatments; instead, it follows patients who receive the Dafodil™ valve to collect real-world information on outcomes. Doctors will monitor patients during their hospital stay and through regular follow-up visits at 1 or 3 months, 1 year, 3 years, and up to 5 years after surgery. Information collected includes survival, heart valve function, complications such as blood clots or infections, heart performance on echocardiography, and quality of life. Participation in this registry is voluntary. All patients must provide written informed consent before joining. Patient privacy will be protected: personal identifiers will not be shared, and data will be coded so individuals cannot be directly identified. The results of this registry will help doctors and health authorities better understand the long-term safety, performance, and durability of the Dafodil™ heart valves in real-world clinical use.

Conditions

Aortic Valve Disease, Mitral Valve Disease, Prosthetic Heart Valve Dysfunction; Valvular Heart Disease Requiring Surgical Aortic or Mitral Valve Replacement

Outcome Measures

Primary Outcomes (1)

• Incidence of Mortality, Thromboembolism, Valve Thrombosis, Paravalvular Leak, and Endocarditis

  Composite of all-cause mortality, thromboembolism, valve thrombosis, major paravalvular leak, and endocarditis following surgical aortic or mitral valve replacement with a bioprosthetic heart valve.

  1 year

Study Arms (1)

Patients undergoing surgical aortic or mitral valve replacement with the Dafodil™ or Dafodil Neo™ pe

Participants undergoing surgical replacement of a native or failed prosthetic aortic or mitral valve using the Dafodil™ or Dafodil Neo™ pericardial bioprosthetic heart valve. Participants are followed prospectively to assess safety and performance outcomes in real-world clinical practice.

Device: Dafodil™ / Dafodil Neo™ Pericardial Bioprosthetic Heart Valve

Interventions

Dafodil™ / Dafodil Neo™ Pericardial Bioprosthetic Heart Valve DEVICE

The Dafodil™ and Dafodil Neo™ pericardial bioprosthetic heart valves are surgically implanted for replacement of a diseased or failed native or prosthetic aortic or mitral valve as part of standard clinical care. This observational registry prospectively follows participants to evaluate the safety and performance of the device in real-world clinical practice.

Patients undergoing surgical aortic or mitral valve replacement with the Dafodil™ or Dafodil Neo™ pe

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with advanced aortic or mitral valvular heart disease undergoing surgical replacement of a native or failed prosthetic valve with a bioprosthetic heart valve in routine clinical practice.

You may qualify if:

• Participant ≥18 years of age
• Participants whose valvular disease is sufficiently advanced to warrant replacement of their natural/prosthetic aortic or mitral valve with Dafodil pericardial bioprosthesis series
• Participants who are willing to undergo all protocol specific study procedures and follow-up requirements

You may not qualify if:

• Participants who are not willing to provide informed consent form, or whose legal heirs object to their participation in the registry
• Participant with active endocarditis, active myocarditis or other systemic infection
• Participants undergoing double valve replacement (DVR)
• Any condition, which, in Investigator's opinion would preclude safe participation of participants in the registry

Sponsors & Collaborators

• Meril Life Sciences Pvt. Ltd.: lead

MeSH Terms

Conditions

Aortic Valve Disease

Condition Hierarchy (Ancestors)

Heart Valve Diseases; Heart Diseases; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2026
• First Posted: January 30, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): December 1, 2033
• Last Updated: February 3, 2026

Record last verified: 2026-01